Conferences

News & Press

Fabric Genomics, a global computational genomics company, and Sentieon, which develops highly optimized algorithms for bioinformatics applications, today announced a technology partnership that will enhance Fabric Genomics’ secondary analysis capabilities within Fabric Enterprise™, the company’s new end-to-end precision medicine platform. Fabric Genomics’ new secondary analysis offering, Fabric Standard™, is 10 times faster than commonly adopted …

Read More

Omicia, Inc., a leading provider of clinical genomic data analysis and reporting tools, was selected to join the Cancer Moonshot’s Blood Profiling Atlas in Cancer (Blood PAC) consortium. In joining Blood PAC, Omicia is demonstrating its commitment to advancing cancer genetics research and extending patients’ lives. The Blood PAC was formed in October 2016 in …

Read More

Omicia, Inc., a leading provider of clinical genome interpretation and reporting software, announced today that San Diego-based Rady Children’s Institute for Genomic Medicine has chosen the company as their first line genome interpretation partner for the implementation of Rady Children’s rapid genome testing in their neonatal and pediatric intensive care units (NICU/ PICU). Stephen Kingsmore, …

Read More

Omicia, Inc., a leading provider of clinical genome interpretation and reporting software, announced today that it has delivered more than 500 clinical reports for the 100,000 Genomes Project, and has begun to return clinical reports for the project’s main program. These clinical reports are being delivered to Genomics England, leader of the 100,000 Genomes Project, and …

Read More

In the recent article “The DNA of a Nation,” Nature magazine highlights the highly-specialized and dedicated clinical interpretation services that Genomics England requires for their 100,000 Genomes Project, which is the first step in bringing genomics to the UK healthcare system. Omicia, the worldwide leader in genome informatics and clinical interpretation, was selected from 28 …

Read More

Omicia, Inc., a leading provider of clinical genome interpretation and reporting software, today announced the completion of a $23 million Series B financing round. Several new investors participated in the round, including UPMC Enterprises, Roche Venture Fund, LDV Partners, Ping An Ventures, and a large genomics investor, as well as existing investors ARTIS Ventures, Acadia …

Read More

Omicia announces the launch of its new ACMG-scoring module for the Opal Clinical™ interpretation and reporting software platform at the 2016 ACMG Annual Clinical Genetics Meeting. This functionality provides an intuitive interface and workflow for clinical testing labs to systematically assess the disease-causing potential of genetic variants using the evidence-based classification system defined in the …

Read More
PRESS | August 27, 2015

The United Kingdom aims to sequence 100,000 human genomes by 2017. But screening them for disease-causing variants will require innovative software. For the 100,000 Genomes Project, it will use Omicia’s Opal Clinical genome interpretation software to assess which variants are likely to be causing disease.  

Read More